//Краткое руководство по ведению пациентов с онкологическими заболеваниями мочеполовой системы

88//

O’Donnell P.H. et al. Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: Results of a phase IB study. J Clin Oncol. 2015;33:296. http://ascopubs.org/doi/abs/10.1200/jco.2015.33.7_suppl.296.

Sharma P. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312. https://www.ncbi.nlm.nih.gov/pubmed/28131785.

Chen D.S., Irving B.A., Hodi F.S. Molecular pathways: next-generation immunotherapy – inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012 Dec 15;18(24):6580-7. doi: 10.1158/1078-0432.CCR-12-1362.

Chen D.S., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013 Jul 25;39(1):1-10. doi: 10.1016/j.immuni.2013.07.012.

Jager D., Jager E., Knuth A. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol. 2001;54:669–674.

Neefjes J., Jongsma M.L., Paul P., Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation [Review]. Nat Rev Immunol. 2011;11:823–836.

Villadangos J.A., Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol. 2007;7:543–555.

Balar A.V. et al. Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210. Journal of Clinical Oncology. 2018 May 20;36(15_suppl):4523-4523. doi: 10.1200/JCO.2018.36.15_suppl.4523.

Sternberg C.N. et al. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. Eur Urol. 2019 Jul;76(1):73-81. doi: 10.1016/j.eururo.2019.03.015. Epub 2019 Mar 23.

Retz M. et al. Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience. BMC Cancer. 2015;15:455. doi: 10.1186/s12885-015-1434-3.

//Краткое руководство по ведению пациентов с онкологическими заболеваниями мочеполовой системы

//89

Médioni J. et al. Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study. BMC Cancer. 2016;16(1):217. doi: 10.1186/s12885-016-2262-9.

Pistamaltzian N. et al. Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group. Anticancer Drugs. 2016;27(1):48–53. doi: 10.1097/CAD.0000000000000297.

Holmsten K. et al. Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis. Oncology Letters. 2016;12:1293–1300. doi.org/10.3892/ol.2016.4775.

Hussain S.A. et al. VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland. Int J Oncol. 2017;50(3):768-772. doi: 10.3892/ijo.2017.3847.

Passalacqua R. et al. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. ASCO. 2016:abstract #e16031. doi: 10.1186/1471-2407-14-779.

Castellano D. et al. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer. 2014 Oct 24;14:779. doi: 10.1186/1471-2407-14-779.

Bellmunt J. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009 Sep 20;27(27):4454-61. doi: 10.1200/JCO.2008.20.5534.

Bellmunt J. et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010 Apr 10;28(11):1850-1855. doi: 10.1200/JCO.2009.25.4599.